IE 11 is not supported. For an optimal experience visit our site on another browser.

VIVUS Inc. is Today's Focus Stock on

/ Source: GlobeNewswire

DALLAS, April 5, 2011 (GLOBE NEWSWIRE) -- announces an investment report featuring VIVUS Inc. (Nasdaq:VVUS). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

The full report is available at:

VIVUS Inc. (VVUS) is a biopharmaceutical company developing innovative, next-generation therapies to address unmet needs in obesity, diabetes, obstructive sleep apnea and sexual health. Its lead product in clinical development, QNEXA, completed phase III clinical trials for the treatment of obesity s currently being considered for approval by U.S. and EU regulators. QNEXA is also in phase II clinical trials for type II diabetes and obstructive sleep apnea. VVUS is also developing an erectile dysfunction drug, Avanafil, that is in phase III clinical trials.

This newsletter has been helping traders make great investment decisions on VVUS; click here for a 25% discount offer.

In the report, the analyst notes:

"Shares of the obesity drug developer soared Monday after it reported that patients taking its experimental weigh loss drug Qnexa over two years saw reductions in blood pressure as well as improvements in lipid levels."

"The data, unveiled at the 60th Annual Scientific Meeting of The American College of Cardiology, also showed that the drug helped patients reduce the number of antihypertensive medications they had to take compared to those taking a dummy drug over two years of treatment, and helped patients achieve a significant weight loss."

To read the entire report visit:

See what investors are saying about VVUS at

Get breaking news on VVUS at is a small-cap research and investment commentary provider. strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on MicroStockProfit please visit: Disclosure is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. is a Web site wholly owned by BlueWave Advisors, LLC. Neither nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. Please read our report and visit our Web site,, for complete risks and disclosures.

CONTACT: Brian Johnson 1-888-307-2850